News Agency News Aggregator Journalist/Editor Broking House Others
AARTIDRUGS - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
AARTIDRUGS - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
#AARTIDRUGS: The forecast dividend for Aarti Drugs Ltd. has increased to ₹6.25 per share from ₹2.5 in the last week.
#AARTIDRUGS: The target price for Aarti Drugs Ltd. has fallen to ₹672.0 from ₹722.0 in the last week.
AARTIDRUGS - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
AARTIDRUGS - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
AARTIDRUGS - Shareholder Meeting / Postal Ballot-Outcome of AGM
#AARTIDRUGS: Aarti Drugs Ltd.'s forecast earnings moved -0.8% over the last month, but the price is -16.4%. It's PE ratio is now 9x earnings.
#AARTIDRUGS: Aarti Drugs Ltd.'s price is -16.4% but the forecast earnings moved -0.0% over the last month.
Around 482 stocks fell to touch their 52-week lows on NSE in Monday's session. Among the stocks that touched their 52-week lows were Aarti Drugs, Accelya Solutions India, Andhra Cements, Aurobindo Pharma, Bank of India, CARE Ratings, CEAT and Central Bank of India.
#AARTIDRUGS: The target price for Aarti Drugs Ltd. has fallen to ₹722.0 from ₹798.67 in the last week.
AARTIDRUGS - Announcement under Regulation 30 (LODR)-Press Release / Media Release
#StocksInNews AARTI DRUGS CRISIL has recently reviewed the Credit Rating and upgraded the Long-Term Rating from 'CRISIL A/Positive' to 'CRISIL A+/Stable' @CNBC_Awaaz #AwaazMarkets
CRISIL upgraded the long-term rating of Aarti Drugs from CRISIL A/Positive to CRISIL 6+/Stable. ICRA re-affirmed the long term credit rating for Rs344.87cr line of credit of V-Guard Industries at ICRA AA.
AARTIDRUGS - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
AARTIDRUGS - Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2019